Abstract: A composition can include a Rho zeolite with a RHO topology having a Si to B ratio or a Si to Al ratio greater than or equal to 8. Making such a composition can include heating an aqueous reaction mixture having a molar ratio of atomic Si to atomic B of about 4 to about 50 or a molar ratio of atomic Si to atomic Al of about 4 to about 50 in the presence of a C4-C6 diquat of N,2-dimethylbenzimidazole structure directing agent to a temperature of at least 75° C. to produce a Rho zeolite.

Abstract: A method of making a molecular sieve may include: reacting a source selected from the group consisting of: a source of a tetrahedral element in the presence of a structure directing agent (SDA) selected from the group consisting of: Ar+-L-Ar, Ar+-L-Ar-L-Ar+, Ar+-L-Ar-L-NR3+, and ArAr+-L-Ar+Ar, where Ar+ is to a N-containing cationic aromatic ring, Ar is to a non-charged aromatic ring, L is a methylene chain of 3-6 carbon atoms, NR3+ is to a quaternary ammonium, and ArAr+ and Ar+Ar are a fused aromatic ring structure comprising both a N-containing cationic portion and a non-charged portion, to produce the molecular sieve.

Abstract: A composition can include a Rho zeolite with a RHO topology having a Si to B ratio or a Si to A1 ratio greater than or equal to 8. Making such a composition can include heating an aqueous reaction mixture having a molar ratio of atomic Si to atomic B of about 4 to about 50 or a molar ratio of atomic Si to atomic Al of about 4 to about 50 in the presence of a C4-C6 diquat of N,2-dimethylbenzimidazole structure directing agent to a temperature of at least 75° C. to produce a Rho zeolite.

Abstract: The zeolite UTD-1 may be formed under hydrothermal synthesis conditions using a directing agent that does not include a metal atom therein. Methods for synthesizing the zeolite UTD-1 may comprise: combining at least a silicon atom source and a directing agent having a structure of in an aqueous medium; forming the zeolite in the aqueous medium under hydrothermal synthesis conditions, such that the zeolite has a framework silicate with a cationic portion of the directing agent occluded within pores or channels of the framework silicate; and isolating the zeolite from the aqueous medium. The zeolite has a powder x-ray diffraction pattern with at least the following 2?scattering angles: 6.0±0.12, 7.6±0.1, 14.66±0.15, 19.7±0.15, 21.27±0.15, 22.13±0.15, 22.61±0.15, and 24.42±0.10 for a borosilicate form zeolite, or 6.0±0.12, 7.6±0.15, 14.55±0.15, 19.64±0.15, 21.01±0.20, 21.90±0.20, 22.34±0.20, and 24.38±0.20 for an aluminosilicate form zeolite.

Abstract: The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: The zeolite UTD-1 may be formed under hydrothermal synthesis conditions using a directing agent that does not include a metal atom therein. Methods for synthesizing the zeolite UTD-1 may comprise: combining at least a silicon atom source and a directing agent having a structure of in an aqueous medium; forming the zeolite in the aqueous medium under hydrothermal synthesis conditions, such that the zeolite has a framework silicate with a cationic portion of the directing agent occluded within pores or channels of the framework silicate; and isolating the zeolite from the aqueous medium. The zeolite has a powder x-ray diffraction pattern with at least the following 2?scattering angles: 6.0±0.12, 7.6±0.1, 14.66±0.15, 19.7±0.15, 21.27±0.15, 22.13±0.15, 22.61±0.15, and 24.42±0.10 for a borosilicate form zeolite, or 6.0±0.12, 7.6±0.15, 14.55±0.15, 19.64±0.15, 21.01±0.20, 21.90±0.20, 22.34±0.20, and 24.38 ±0.20 for an aluminosilicate form zeolite.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: A process for synthesizing a DDR framework-type molecular sieve comprises crystallizing a reaction mixture comprising water, a source of silicon, and a structure directing agent, Q, selected from the group consisting of a methyltropinium salt, a 2,6,N,N-tetramethylpiperidinium salt, a 2,N,N-trimethylpiperidinium salt and mixtures thereof, wherein the reaction mixture has a molar ratio of water to silicon from 5 to 80 and a molar ratio of alkali or alkaline earth metal, M, to silicon less than 0.01.

Abstract: A process for synthesizing a DDR framework-type molecular sieve comprises crystallizing a reaction mixture comprising water, a source of silicon, and a structure directing agent, Q, selected from the group consisting of a methyltropinium salt, a 2,6,N,N-tetramethylpiperidinium salt, a 2,N,N-trimethylpiperidinium salt and mixtures thereof, wherein the reaction mixture has a molar ratio of water to silicon from 5 to 80 and a molar ratio of alkali or alkaline earth metal, M, to silicon less than 0.01.

Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.

Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.

Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.

Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.

Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.

Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.

Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 are independent substituents or are fused to form spirocyclic rings; R3, RC, and R4 are as defined herein; and R5 is a substituted benzene ring or a substituted five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms including O, S, SO, SO2 or NR6; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.